Loading...
International projects source: SICRIS

European Cohort coordinating network on HIV drug resistance

Researchers (1)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  22461  PhD Dunja Babič  Microbiology and immunology  Head  2006 - 2010  37 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0381  University of Ljubljana, Faculty of Medicine  Ljubljana  1627066  48,203 
Abstract
This project is aimed at COORDINATING EUROPEAN CLINICAL COHORT STUDIES IN THE AREA OF HIV ANTIVIRAL RESISTANCE.The main result of this coordination action will be the creation and maintenance of a pan-European cohort (including Central- and Eastern European countries) maintained by a network of virological reference centres in over 30 European countries, to study the appearance, spread and clinical consequences of HIV resistance under joint standards and linked to a common shared self sustainable database.In addition to coordinating the cohort on HIV resistance, active exchange of good practices and standards is sought with the other European HIV/Aids cohorts studying morbidity and mortality of HIV/Aids both in adults and children, mother-to-child transmission, through the proposed organisation and follow-up of periodic strategic meetings with coordinators of PENTA, CASCADE, EuroSIDA, ECS, the European Commission and the EU Centre of Disease Control (ECDC).By the actions proposed in this coordination action, a major contribution is being made to- decreasing the fragmentation of HIV resistance research in Central- and Eastern Europe,- increasing the level of virological expertise and skills in HIV resistance in this region and- the desired exchange of good practices between the HIV/AIDS cohorts in Europe and the WHO.This increased coordination made possible by EuroHIVResistance will lead to new coordinated data and knowledge on transmission, prevalence and factors facilitating the emergence and spread of drug resistant HIV in Europe, providing the pharmaceutical industry, scientific community and public health authorities with valuable new input for the development of new drugs, new treatment recommendations, intervention programmes and prophylactic guidelines necessary to effectively confront the global emergency caused by HIV.
Views history
Favourite